Previous 10 | Next 10 |
Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine Four poster presentations to feature: biomarker genomic studies from pivotal INSPIRE Trial a novel adaptive trial design for a pivotal Phase 3 Study...
Thinly traded nano cap Onconova Therapeutics (NASDAQ: ONTX ) slips 4% premarket on light volume in reaction to its preliminary prospectus for a public offering of up to ~16.9M Units. More news on: Onconova Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Re...
NEWTOWN, Pa., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), announced that the Company believes it ...
Gainers: TrovaGene (NASDAQ: TROV ) +65% . Biogen (NASDAQ: BIIB ) +29% . Stamps.com (NASDAQ: STMP ) +24% . Teekay Corporation (NYSE: TK ) +22% . Cision (NYSE: CISN ) +19% . Teekay LNG Partners (NYSE: TGP ) +17% . Obalon Therapeutics (NASDAQ: OBLN ) +14%. Athenex (NASDAQ: ...
Gainers: Interlink Electronics ( OTCPK:LINK ) +37% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +33% . Arotech Corporation (NASDAQ: ARTX ) +31% . Plus Therapeutics (NASDAQ: PSTV ) +25% . Cesca Therapeutics (NASDAQ: KOOL ) +20% . PriceSmart (NASDAQ: PSMT ) +18% . Dova Pharmaceuticals...
Onconova Therapeutics (NASDAQ: ONTX ) is down 24% after entering into securities purchase agreements with certain institutional investors to purchase 2,136,193 common shares at $1.60/share in a registered direct offering for aggregate gross proceeds of ~$3.4M. More news on: O...
Reebonz Holding (NASDAQ: RBZ ) -32% on 1H earnings . More news on: Reebonz Holding Limited, Onconova Therapeutics, Inc., Overstock.com, Inc., Stocks on the move, Read more ...
NEWTOWN, Pa., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) , a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that it has entered into ...
NEWTOWN, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS) today announced that it has decided to terminate t...
Zynerba Pharmaceuticals (NASDAQ: ZYNE ) -14% on possible Zygel safety signal . More news on: Zynerba Pharmaceuticals, Inc., FedEx Corporation, Onconova Therapeutics, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Onconova Therapeutics Inc. Company Name:
ONTX Stock Symbol:
NASDAQ Market:
Onconova Therapeutics Inc. Website:
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines Funding expected to ...
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onco...
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines Funding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; tra...